

BioSpecifics Technologies Corp. to Present at BioCentury Future Leaders in the Biotech Industry Conference

LYNBROOK, NY – April 13, 2011 - BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming BioCentury Future Leaders in the Biotech Industry Conference on Friday, April 15th, 2011, at 3:00 p.m. EDT at the Millennium Broadway Hotel in New York City.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at <http://www.biospecifics.com>, or you may use the link: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=BSTC&item_id=3960783.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications, three of which include: Dupuytren's contracture, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium markets XIAFLEX[®] in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAPEX[®] in Europe and has announced European regulatory approval and the first commercial sale in the United Kingdom. More information about BioSpecifics may be found on its website at www.biospecifics.com.

Contact:

BioSpecifics Technologies Corp.
Thomas L. Wegman, President
(516) 593-7000
thomas_wegman@biospecifics.com